(Q35779346)

10 August 2017

1 reference

title

Drugs and the retina (English)

1 reference

10 August 2017

Munir Pirmohamed

2

0 references

author name string

Simon Constable

series ordinal

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Drug Safety

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

249-259

1 reference

Medications and retinal toxicity

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Ocular adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Binding of drugs to eye melanin is not predictive of ocular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual field constriction in children with epilepsy on vigabatrin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual field defects associated with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual field defects associated with vigabratin monotherapy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Peripheral retinal dysfunction in patients taking vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Symptomatic and asymptomatic visual loss in patients taking vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Second study supports results of Whitehall study after retirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual function loss from vigabatrin: effect of stopping the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual field defects with vigabatrin: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

A controlled study of vigabatrin and visual abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Vigabatrin visual toxicity: evolution and dose dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Guideline may help in prescribing vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Examining visual field defects in the paediatric population exposed to vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Is chloroquine obsolete in treatment of rheumatic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Risks and benefits of prophylactic antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Delayed-onset chloroquine retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Ocular toxicity and hydroxychloroquine: guidelines for screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Screening for hydroxychloroquine retinal toxicity: is it necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Ocular Adverse Effects of Neuropsychiatric Agents Incidence and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Adverse ocular reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Welding arc maculopathy and fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Anterior ischemic optic neuropathy associated with viagra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Sildenafil (Viagra) and ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

The toxic effects of desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

The management of cytomegalovirus retinitis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Foscarnet and crystals in glomerular capillary lumens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Iritis associated with intravenous cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.249

21 January 2018

Identifiers

DOI

10.1517/14740338.3.3.249

1 reference

10 August 2017

1 reference